Mendus

.Hero-module--bg-image--629a6:before { opacity: 1; background-image: url('/static/e62925564ecb1ec6ce1d956cde68e06b/44759/2026-granddad-child-reading-landscape-scaled.jpg'); }

Changing the course of cancer treatmentWe explore the power of the immune system to improve long-term survival of cancer patients, while preserving health and quality of life.
About us
<picture><source type="image/webp" srcSet="/static/733f50bbc0e2fdc1ab5eff8741149228/bde29/260716-Mendus-SAHMRI-WEBSITE.webp 227w,/static/733f50bbc0e2fdc1ab5eff8741149228/58906/260716-Mendus-SAHMRI-WEBSITE.webp 454w,/static/733f50bbc0e2fdc1ab5eff8741149228/b7017/260716-Mendus-SAHMRI-WEBSITE.webp 907w" sizes="(min-width: 907px) 907px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 907px) 907px, 100vw" decoding="async" loading="lazy" src="/static/733f50bbc0e2fdc1ab5eff8741149228/b4646/260716-Mendus-SAHMRI-WEBSITE.jpg" srcSet="/static/733f50bbc0e2fdc1ab5eff8741149228/1c00b/260716-Mendus-SAHMRI-WEBSITE.jpg 227w,/static/733f50bbc0e2fdc1ab5eff8741149228/e7daf/260716-Mendus-SAHMRI-WEBSITE.jpg 454w,/static/733f50bbc0e2fdc1ab5eff8741149228/b4646/260716-Mendus-SAHMRI-WEBSITE.jpg 907w" alt=""/></picture>
Mendus collaborates with SAHMRI in preparation for VITAL-TFR2Learn more here
<picture><source type="image/webp" srcSet="/static/1f89b09994ff09a9611147deb1836014/bde29/260708-VITAL-CML-WEBSITE.webp 227w,/static/1f89b09994ff09a9611147deb1836014/58906/260708-VITAL-CML-WEBSITE.webp 454w,/static/1f89b09994ff09a9611147deb1836014/b7017/260708-VITAL-CML-WEBSITE.webp 907w" sizes="(min-width: 907px) 907px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 907px) 907px, 100vw" decoding="async" loading="lazy" src="/static/1f89b09994ff09a9611147deb1836014/b4646/260708-VITAL-CML-WEBSITE.jpg" srcSet="/static/1f89b09994ff09a9611147deb1836014/1c00b/260708-VITAL-CML-WEBSITE.jpg 227w,/static/1f89b09994ff09a9611147deb1836014/e7daf/260708-VITAL-CML-WEBSITE.jpg 454w,/static/1f89b09994ff09a9611147deb1836014/b4646/260708-VITAL-CML-WEBSITE.jpg 907w" alt=""/></picture>
Promising immunological data from CADENCE and VITAL-CMLRead more
<picture><source type="image/webp" srcSet="/static/ef3780dbf5e17882b36828f0b339e07a/bde29/261112-Q3-FR-WEBSITE.webp 227w,/static/ef3780dbf5e17882b36828f0b339e07a/58906/261112-Q3-FR-WEBSITE.webp 454w,/static/ef3780dbf5e17882b36828f0b339e07a/b7017/261112-Q3-FR-WEBSITE.webp 907w" sizes="(min-width: 907px) 907px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 907px) 907px, 100vw" decoding="async" loading="lazy" src="/static/ef3780dbf5e17882b36828f0b339e07a/a03a1/261112-Q3-FR-WEBSITE.png" srcSet="/static/ef3780dbf5e17882b36828f0b339e07a/3403c/261112-Q3-FR-WEBSITE.png 227w,/static/ef3780dbf5e17882b36828f0b339e07a/3e108/261112-Q3-FR-WEBSITE.png 454w,/static/ef3780dbf5e17882b36828f0b339e07a/a03a1/261112-Q3-FR-WEBSITE.png 907w" alt=""/></picture>
Mendus publishes Q3 2026 financial reportRead the press release
<picture><source type="image/webp" srcSet="/static/4500665f26ce306f14cdb18f8de4615d/bde29/061008-Hans-COO.webp 227w,/static/4500665f26ce306f14cdb18f8de4615d/58906/061008-Hans-COO.webp 454w,/static/4500665f26ce306f14cdb18f8de4615d/b7017/061008-Hans-COO.webp 907w" sizes="(min-width: 907px) 907px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 907px) 907px, 100vw" decoding="async" loading="lazy" src="/static/4500665f26ce306f14cdb18f8de4615d/b4646/061008-Hans-COO.jpg" srcSet="/static/4500665f26ce306f14cdb18f8de4615d/1c00b/061008-Hans-COO.jpg 227w,/static/4500665f26ce306f14cdb18f8de4615d/e7daf/061008-Hans-COO.jpg 454w,/static/4500665f26ce306f14cdb18f8de4615d/b4646/061008-Hans-COO.jpg 907w" alt=""/></picture>
Hans Preusting appointed COORead the press release
<picture><source type="image/webp" srcSet="/static/68f26fe34509e1e6556b7b770d71a6ed/bde29/260911-VITAL-CML-stage-1-WEBSITE.webp 227w,/static/68f26fe34509e1e6556b7b770d71a6ed/58906/260911-VITAL-CML-stage-1-WEBSITE.webp 454w,/static/68f26fe34509e1e6556b7b770d71a6ed/b7017/260911-VITAL-CML-stage-1-WEBSITE.webp 907w" sizes="(min-width: 907px) 907px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 907px) 907px, 100vw" decoding="async" loading="lazy" src="/static/68f26fe34509e1e6556b7b770d71a6ed/b4646/260911-VITAL-CML-stage-1-WEBSITE.jpg" srcSet="/static/68f26fe34509e1e6556b7b770d71a6ed/1c00b/260911-VITAL-CML-stage-1-WEBSITE.jpg 227w,/static/68f26fe34509e1e6556b7b770d71a6ed/e7daf/260911-VITAL-CML-stage-1-WEBSITE.jpg 454w,/static/68f26fe34509e1e6556b7b770d71a6ed/b4646/260911-VITAL-CML-stage-1-WEBSITE.jpg 907w" alt=""/></picture>
Positive VITAL-CML read-outRead more
<picture><source type="image/webp" srcSet="/static/733f50bbc0e2fdc1ab5eff8741149228/bde29/260716-Mendus-SAHMRI-WEBSITE.webp 227w,/static/733f50bbc0e2fdc1ab5eff8741149228/58906/260716-Mendus-SAHMRI-WEBSITE.webp 454w,/static/733f50bbc0e2fdc1ab5eff8741149228/b7017/260716-Mendus-SAHMRI-WEBSITE.webp 907w" sizes="(min-width: 907px) 907px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 907px) 907px, 100vw" decoding="async" loading="lazy" src="/static/733f50bbc0e2fdc1ab5eff8741149228/b4646/260716-Mendus-SAHMRI-WEBSITE.jpg" srcSet="/static/733f50bbc0e2fdc1ab5eff8741149228/1c00b/260716-Mendus-SAHMRI-WEBSITE.jpg 227w,/static/733f50bbc0e2fdc1ab5eff8741149228/e7daf/260716-Mendus-SAHMRI-WEBSITE.jpg 454w,/static/733f50bbc0e2fdc1ab5eff8741149228/b4646/260716-Mendus-SAHMRI-WEBSITE.jpg 907w" alt=""/></picture>
Mendus collaborates with SAHMRI in preparation for VITAL-TFR2Learn more here
<picture><source type="image/webp" srcSet="/static/1f89b09994ff09a9611147deb1836014/bde29/260708-VITAL-CML-WEBSITE.webp 227w,/static/1f89b09994ff09a9611147deb1836014/58906/260708-VITAL-CML-WEBSITE.webp 454w,/static/1f89b09994ff09a9611147deb1836014/b7017/260708-VITAL-CML-WEBSITE.webp 907w" sizes="(min-width: 907px) 907px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 907px) 907px, 100vw" decoding="async" loading="lazy" src="/static/1f89b09994ff09a9611147deb1836014/b4646/260708-VITAL-CML-WEBSITE.jpg" srcSet="/static/1f89b09994ff09a9611147deb1836014/1c00b/260708-VITAL-CML-WEBSITE.jpg 227w,/static/1f89b09994ff09a9611147deb1836014/e7daf/260708-VITAL-CML-WEBSITE.jpg 454w,/static/1f89b09994ff09a9611147deb1836014/b4646/260708-VITAL-CML-WEBSITE.jpg 907w" alt=""/></picture>
Promising immunological data from CADENCE and VITAL-CMLRead more

<picture><source type="image/webp" srcSet="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/d7070/Startpage_1-NEW-1.webp 240w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/4ce17/Startpage_1-NEW-1.webp 480w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/95cd0/Startpage_1-NEW-1.webp 960w" sizes="(min-width: 960px) 960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 960px) 960px, 100vw" decoding="async" loading="lazy" src="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/49439/Startpage_1-NEW-1.jpg" srcSet="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/ff13b/Startpage_1-NEW-1.jpg 240w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/28e6b/Startpage_1-NEW-1.jpg 480w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/49439/Startpage_1-NEW-1.jpg 960w" alt=""/></picture>
Gaining the 
upper handToday, tumor recurrence is the main cause of cancer-related deaths. We aim to reduce tumor recurrence by harnessing the immune system to act against residual cancer cells.
What we do

<picture><source type="image/webp" srcSet="/static/0237bef387e76cffaa6681d16a2b59c4/8cdf4/Startpage_3.webp 302w,/static/0237bef387e76cffaa6681d16a2b59c4/39272/Startpage_3.webp 603w,/static/0237bef387e76cffaa6681d16a2b59c4/0d01b/Startpage_3.webp 1206w" sizes="(min-width: 1206px) 1206px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1206px) 1206px, 100vw" decoding="async" loading="lazy" src="/static/0237bef387e76cffaa6681d16a2b59c4/e579d/Startpage_3.jpg" srcSet="/static/0237bef387e76cffaa6681d16a2b59c4/8f82e/Startpage_3.jpg 302w,/static/0237bef387e76cffaa6681d16a2b59c4/d2caf/Startpage_3.jpg 603w,/static/0237bef387e76cffaa6681d16a2b59c4/e579d/Startpage_3.jpg 1206w" alt="&lt;p&gt;Molecular Structure. Science background. 3D Render&lt;/p&gt;
"/></picture>
Invest in future cancer careMendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.
Investors

Latest newsNews and Events
No articles found

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89:before { opacity: 1; background-image: url('/static/58920a993c01776af52e6d8a69a7452d/60e72/What-we-do_1-mobile-1.jpg'); }

What we do

Changing the course of cancer treatment

Mendus collaborates with SAHMRI in preparation for VITAL-TFR2

Promising immunological data from CADENCE and VITAL-CML

Mendus publishes Q3 2026 financial report

Hans Preusting appointed COO

Positive VITAL-CML read-out

Mendus collaborates with SAHMRI in preparation for VITAL-TFR2

Promising immunological data from CADENCE and VITAL-CML

Gaining the upper hand

Invest in future cancer care

Latest news

What we do

Gaining the
upper hand